Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease hartnup disease
Comorbidity C0007131|nsclc
Sentences 9
PubMedID- 22943793 In non-small cell lung carcinoma (nsclc), elevated expression of tgf-β correlates with disease progression[232].
PubMedID- 21655094 Clinically, both egfr-tkis showed good tolerability and antitumor activity in nsclc patients with disease progressing after first line platinum-based chemotherapy [5], [8], [9].
PubMedID- 24505469 In nsclc, cnas increase with disease progression and cnas are both positionally and functionally clustered [17].
PubMedID- 22307026 However, due to sensitivity constraints in current enrichment-based ctc detection technologies, there are few published data about ctc prevalence rates and morphologic heterogeneity in early-stage nsclc, or the correlation of ctcs with disease progression and their usability for clinical staging.
PubMedID- 25622640 Patients were deemed eligible in the presence of histologically or cytologically confirmed metastatic nsclc, with disease control after 4–6 cycles of first-line platinum-based chemotherapy.
PubMedID- 22276032 A decrease in segfr during treatment with gefitinib has been recognized to correlate with disease control in patients with nsclc [24].
PubMedID- 25810955 Four hundred and twenty four nsclc patients with disease progression after chemotherapy were randomly assigned to receive erlotinib or chemotherapy (standard docetaxel or pemetrexed).
PubMedID- 24265521 We retrospectively reviewed 81 advanced nsclc patients with disease progression following tumor response and durable (≥ 6 months) disease stabilization with first-line or second-line gefitinib.
PubMedID- 25740118 Eligibility stipulated a diagnosis of nsclc with disease “unsuitable for either attempted curative resection or radical rt or recurrent intrathoracic cancer outside any previously radiated volume.” the overall radiographic response rate was higher in rt plus fluorouracil (29% vs 16%, p = .035).

Page: 1